Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess the Safety and Immunogenicity of a Booster Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Vaccinated Against COVID-19.

NCT05246137 is registered in ClinicalTrials.gov with Hipra Scientific, S.L.U as lead sponsor.

NCT NCT05246137
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05246137 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III, Open Label, Single Arm, Multi-centre, Trial to Assess the Safety and Immunogenicity of a Booster Vaccination With a Recombinant Protein RBD Fusion Heterodimer Candidate (PHH-1V) Against SARS-CoV-2, in Adults Vaccinated Against COVID-19.
Lead sponsor
Hipra Scientific, S.L.U
Phase
Phase 3
Overall status
Completed
Start date
February 3, 2022
Completion date
March 3, 2023
Enrollment
2,646 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 acute respiratory disease